FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport.
AKT
Colon cancer
Epithelial–mesenchymal transition
Fatty acid binding protein 4
Lipid
Metastasis
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
06
2020
accepted:
28
09
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
23
10
2020
Statut:
epublish
Résumé
The prognosis of colon cancer is poor for metastasis, while the mechanism, especially adipocytes related, is not yet clear. The purpose of this study is to determine the effects of fatty acid binding protein 4 (FABP4), a transporter for lipids, on colon cancer progression. The distribution of lipids and FABP4 was tested in the colon cancer tissues and adjacent normal tissues, and their relationship was also verified in vitro. Experiments about cellular invasion, migration and proliferation were performed to detect the impacts of FABP4 on the biological behaviors of colon cancer, and the positive results were checked in vivo. Meanwhile, the regulatory role of FABP4 in the energy and lipid metabolism was evaluated by the levels of triglyceride, ATP, LDH, glycerol and NEFA. At last, GO and KEGG analysis based on FABP4 overexpressed cells was performed, and the AKT pathway and epithelial-mesenchymal transition (EMT)-related proteins were determined by Western blot. Higher accumulation of lipids and stronger FABP4 transcription were observed in colon cancer tissues. Having been incubated with adipose tissue extract and overexpressed FABP4, colon cancer cells demonstrated enhanced lipid accumulation. In functional experiments, co-culture with adipose tissue extract significantly enhanced the invasion and migration of colon cancer cells, as well as the energy and lipid metabolism, and all these processes were reversed by FABP4 inhibitor. In addition, the metastasis of FABP4-overexpressed colon cancer cells was also significantly enhanced in vitro and in vivo. In terms of mechanism, the bioinformatics analysis showed that FABP4 was enriched in 11 pathways related to metabolic processes in FABP4 overexpressed cells. Finally, FABP4 overexpression improved EMT progression of colon cancer, as evidenced by the upregulation of Snail, MMP-2 and MMP-9, the downregulation of E-cadherin. The expression of p-Akt was also elevated. FABP4 overexpression could increase FAs transport to enhance energy and lipid metabolism, and activate AKT pathway and EMT to promote the migration and invasion of colon cancer cells.
Sections du résumé
BACKGROUND
BACKGROUND
The prognosis of colon cancer is poor for metastasis, while the mechanism, especially adipocytes related, is not yet clear. The purpose of this study is to determine the effects of fatty acid binding protein 4 (FABP4), a transporter for lipids, on colon cancer progression.
METHODS
METHODS
The distribution of lipids and FABP4 was tested in the colon cancer tissues and adjacent normal tissues, and their relationship was also verified in vitro. Experiments about cellular invasion, migration and proliferation were performed to detect the impacts of FABP4 on the biological behaviors of colon cancer, and the positive results were checked in vivo. Meanwhile, the regulatory role of FABP4 in the energy and lipid metabolism was evaluated by the levels of triglyceride, ATP, LDH, glycerol and NEFA. At last, GO and KEGG analysis based on FABP4 overexpressed cells was performed, and the AKT pathway and epithelial-mesenchymal transition (EMT)-related proteins were determined by Western blot.
RESULTS
RESULTS
Higher accumulation of lipids and stronger FABP4 transcription were observed in colon cancer tissues. Having been incubated with adipose tissue extract and overexpressed FABP4, colon cancer cells demonstrated enhanced lipid accumulation. In functional experiments, co-culture with adipose tissue extract significantly enhanced the invasion and migration of colon cancer cells, as well as the energy and lipid metabolism, and all these processes were reversed by FABP4 inhibitor. In addition, the metastasis of FABP4-overexpressed colon cancer cells was also significantly enhanced in vitro and in vivo. In terms of mechanism, the bioinformatics analysis showed that FABP4 was enriched in 11 pathways related to metabolic processes in FABP4 overexpressed cells. Finally, FABP4 overexpression improved EMT progression of colon cancer, as evidenced by the upregulation of Snail, MMP-2 and MMP-9, the downregulation of E-cadherin. The expression of p-Akt was also elevated.
CONCLUSION
CONCLUSIONS
FABP4 overexpression could increase FAs transport to enhance energy and lipid metabolism, and activate AKT pathway and EMT to promote the migration and invasion of colon cancer cells.
Identifiants
pubmed: 33088219
doi: 10.1186/s12935-020-01582-4
pii: 1582
pmc: PMC7574203
doi:
Types de publication
Journal Article
Langues
eng
Pagination
512Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Nat Rev Clin Oncol. 2017 Feb;14(2):85-99
pubmed: 27502359
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
J Am Coll Nutr. 2015;34(3):244-54
pubmed: 25760239
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Biochim Biophys Acta. 2012 Jul;1818(7):1691-7
pubmed: 22446190
Cell Metab. 2014 Aug 5;20(2):280-94
pubmed: 25017943
Obes Surg. 2015 Jan;25(1):109-18
pubmed: 24993523
Clin Exp Metastasis. 2012 Apr;29(4):381-95
pubmed: 22322279
Nat Cell Biol. 2014 Jun;16(6):488-94
pubmed: 24875735
PLoS One. 2016 Jun 13;11(6):e0157372
pubmed: 27294862
Mol Cell Endocrinol. 2018 Feb 15;462(Pt B):107-118
pubmed: 28163102
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):737-46
pubmed: 22492832
Clin Med Insights Cardiol. 2015 Feb 02;8(Suppl 3):23-33
pubmed: 25674026
PLoS One. 2015 Mar 09;10(3):e0119473
pubmed: 25751270
J Hepatol. 2017 Feb;66(2):424-441
pubmed: 27686679
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
World J Stem Cells. 2015 Mar 26;7(2):253-65
pubmed: 25815113
Biochimie. 2019 Oct;165:229-234
pubmed: 31401189
Cancer Discov. 2016 Aug;6(8):852-69
pubmed: 27246539
Mol Carcinog. 2017 Jan;56(1):208-217
pubmed: 27061264
J Theor Biol. 2015 Jan 7;364:344-54
pubmed: 25280936
Cell Death Dis. 2018 Jul 23;9(8):798
pubmed: 30038258
Cancer Res. 2015 Apr 1;75(7):1161-8
pubmed: 25736688
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Int J Cancer. 2014 Dec 1;135(11):2558-68
pubmed: 24740818
Stem Cells. 2016 Aug;34(8):2183-93
pubmed: 27250566
Hum Pathol. 2014 Nov;45(11):2318-25
pubmed: 25281027
Oncogene. 2017 Feb 16;36(7):912-921
pubmed: 27568980
Obes Rev. 2015 Feb;16 Suppl 1:36-44
pubmed: 25614202
PLoS One. 2015 Mar 06;10(3):e0119348
pubmed: 25747684
Urol Oncol. 2015 Mar;33(3):113.e9-17
pubmed: 25192834
Phytother Res. 2016 Nov;30(11):1802-1808
pubmed: 27406217
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302